Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Immunogen Inc (IMGN)  
$31.23 0.00 (0.00%) as of 4:30 Thu 2/8


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 264,900,000
Market Cap: 8.27(B)
Last Volume: 49,305,461 Avg Vol: 5,854,790
52 Week Range: $4.32 - $31.23
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  606
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 39,348 1,060,446 4,785,085 4,785,085
Total Sell Value $1,152,494 $23,992,060 $86,338,289 $86,338,289
Total People Sold 4 5 5 5
Total Sell Transactions 4 17 26 26
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 257
  Page 5 of 11  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Coen Stacy Ann SVP & CHIEF BUSINESS OFFICER   •       –      –    2022-06-30 4 A $3.83 $12,783 D/D 3,342 7,168     -
   Lentini Renee V.P.-FIN., PRIN. ACCTG. OFF.   •       –      –    2022-06-30 4 A $3.83 $9,597 D/D 2,509 18,297     -
   Berkenblit Anna SVP & CHIEF MEDICAL OFFICER   •       –      –    2022-06-30 4 A $3.83 $11,754 D/D 3,073 110,235     -
   Coen Stacy Ann SVP & Chief Business Officer   •       –      –    2021-12-31 4 A $5.60 $8,378 D/D 1,496 3,826     -
   Wingrove Theresa SVP of Regulatory Affairs   •       –      –    2021-12-31 4 A $5.60 $11,486 D/D 2,051 79,569     -
   Lentini Renee V.P.-Fin., Prin. Acctg. Off.   •       –      –    2021-12-31 4 A $5.60 $10,959 D/D 1,957 15,788     -
   Berkenblit Anna SVP & Chief Medical Officer   •       –      –    2021-12-31 4 A $5.60 $9,862 D/D 1,761 107,162     -
   Mitchell Dean J Director   –       •      –    2021-09-03 4 OE $1.84 $321,400 D/D 83,000 93,000     -
   Wingrove Theresa SVP of Regulatory Affairs   •       –      –    2021-06-30 4 A $5.52 $9,759 D/D 1,768 77,518     -
   Berkenblit Anna SVP & Chief Medical Officer   •       –      –    2021-06-30 4 A $5.52 $11,382 D/D 2,062 105,401     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2021-06-30 4 A $5.52 $21,246 D/D 3,849 432,866     -
   Ryll Thomas SVP, Technical Operations   •       –      –    2021-06-30 4 A $5.52 $21,246 D/D 3,849 84,714     -
   Lentini Renee V.P.-Fin., Prin. Acctg. Off.Of   •       –      –    2021-01-01 3 IO $0.00 $0 D/D 0 12,148 -1%     
   Wingrove Theresa VP of Regulatory Affairs   •       –      –    2020-12-31 4 A $4.04 $10,742 D/D 2,659 75,750     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2020-12-31 4 A $4.04 $1,462 D/D 362 38,274     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2020-12-31 4 A $4.04 $8,900 D/D 2,203 103,339     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2020-12-22 4 GD $0.00 $0 D/D 10,000 429,017     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2020-07-01 4 A $3.91 $1,337 D/D 342 21,724     -
   Berkenblit Anna VP & Chief Medical Officer   •       –      –    2020-06-30 4 A $3.91 $11,914 D/D 3,047 101,136     -
   Enyedy Mark J Chief Executive Officer   •       •      –    2020-06-30 4 A $3.91 $20,492 D/D 5,241 439,017     -
   Ryll Thomas VP, Technical Operations   •       –      –    2020-06-30 4 A $3.91 $20,492 D/D 5,241 80,865     -
   Wingrove Theresa VP of Regulatory Affairs   •       –      –    2020-06-30 4 A $3.91 $10,139 D/D 2,593 73,091     -
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2020-04-02 4 S $3.43 $18,687 D/D (5,448) 21,382 -11%     
   Foster David G V.P.-Fin., Prin. Acctg. Off.   •       –      –    2020-04-01 4 OE $0.00 $0 D/D 18,160 26,830     -
   Ryll Thomas SVP, Technical Operations   •       –      –    2020-02-24 4 AS $4.99 $83,782 D/D (16,790) 75,624 -4%     
  257 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 11
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us